ReWalk Robotics announces the Appointment of Randel E. Richner, BSN, MPH to its Board of Directors
October 19 2020 - 7:01AM
ReWalk Robotics. Ltd. (NASDAQ: RWLK) (“ReWalk” or the “Company”)
announced today that the Company has approved the appointment of
Randel Richner to the Board of Directors, effective November 1,
2020.
Ms. Richner’s extensive history experience in
health policy, reimbursement, economics and data analytics includes
serving as the industry representative on the Centers for Medicare
& Medicaid Services’ (“CMS”) Medicare Coverage Advisory
Committee; service on the Executive Dean’s Advisory Board at the
University of Michigan’s School of Public Health; establishing the
global reimbursement and economics function at Boston Scientific as
that organization’s Vice President of Global Government Affairs and
Reimbursement and in founding Neocure, a firm that advised industry
on health care policy.
Jeff Dykan, Chairman of ReWalk Robotics states,
“As ReWalk advances its commercialization pathway, Randel has an
ideal combination of operating industry knowledge and reimbursement
policy establishment. Her decision to accept an appointment to our
Board will benefit the entire industry with her participation in
strategic decisions and in helping guide government policy for
exoskeletons.”
Ms. Richner received a Master of Public Health
in Health Policy and Administration and a Bachelor of Science in
Nursing from the University of Michigan in Ann Arbor, Michigan.
“Throughout my career, I have sought to enable
access to breakthrough technologies as an important element of
public health policy. Providing guidance with the ReWalk Board for
business strategies that allow individuals to walk again matches my
goals in advancing health options for the disabled community,” said
Ms. Richner.
For more information, please visit
www.rewalk.com.
About ReWalk Robotics
Ltd.ReWalk Robotics Ltd. develops, manufactures and
markets wearable robotic exoskeletons for individuals with lower
limb disabilities as a result of spinal cord injury or stroke.
ReWalk's mission is to fundamentally change the quality of life for
individuals with lower limb disability through the creation and
development of market leading robotic technologies. Founded in
2001, ReWalk has headquarters in the United
States, Israel and Germany. For more information on
the ReWalk systems, please visit www.rewalk.com.ReWalk® is a
registered trademark of ReWalk Robotics Ltd. in Israel
and the United States.ReStore® is a registered trademark
of ReWalk Robotics Ltd. in Europe and an
allowed trademark in the United States.
Forward-Looking StatementsIn
addition to historical information, this press release contains
forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of
1995, Section 27A of the U.S. Securities Act of 1933, and
Section 21E of the U.S. Securities Exchange Act of 1934.
Such forward-looking statements may include projections regarding
ReWalk's future performance and other statements that are not
statements of historical fact and, in some cases, may be identified
by words like "anticipate," "assume," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "future," "will," "should,"
"would," "seek" and similar terms or phrases. The forward-looking
statements contained in this press release are based on
management's current expectations, which are subject to
uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of ReWalk's control.
Important factors that could cause ReWalk's actual results to
differ materially from those indicated in the forward-looking
statements include, among others: ReWalk's management's conclusion,
and its independent registered public accounting firm's statement
in its opinion relating to its consolidated financial statements
for the fiscal year ended December 31, 2019, that there is a
substantial doubt as to the Company's ability to continue as a
going concern; the current COVID-19 pandemic has adversely affected
and may continue to affect adversely business and results of
operations; ReWalk's ability to have sufficient funds to meet
certain future capital requirements, which could impair the
Company's efforts to develop and commercialize existing and new
products; ReWalk's ability to maintain compliance with the
continued listing requirements of the Nasdaq Capital Market and the
risk that its ordinary shares will be delisted if it cannot do so;
ReWalk's ability to establish a pathway to commercialize its
products in China; ReWalk's ability to maintain and grow its
reputation and the market acceptance of its products; ReWalk's
ability to achieve reimbursement from third-party payors for its
products; ReWalk's limited operating history and its ability to
leverage its sales, marketing and training infrastructure; ReWalk's
expectations as to its clinical research program and clinical
results; ReWalk's expectations regarding future growth, including
its ability to increase sales in its existing geographic markets
and expand to new markets; ReWalk's ability to obtain certain
components of its products from third-party suppliers and its
continued access to its product manufacturers; ReWalk's ability to
repay its secured indebtedness; ReWalk's ability to improve its
products and develop new products; ReWalk's compliance with medical
device reporting regulations to report adverse events involving the
Company's products, which could result in voluntary corrective
actions or enforcement actions such as mandatory recalls, and the
potential impact of such adverse events on ReWalk's ability to
market and sell its products; ReWalk's ability to gain and maintain
regulatory approvals; ReWalk's expectations as to the results of,
and the Food and Drug Administration's potential
regulatory developments with respect to its mandatory 522
postmarket surveillance study; ReWalk's ability to maintain
adequate protection of its intellectual property and to avoid
violation of the intellectual property rights of others; the risk
of a cybersecurity attack or breach of the Company's IT systems
significantly disrupting its business operations; the impact of
substantial sales of the Company's shares by certain shareholders
on the market price of the Company's ordinary shares; ReWalk's
ability to use effectively the proceeds of its offerings of
securities; the risk of substantial dilution resulting from the
periodic issuances of ReWalk's ordinary shares; the impact of the
market price of the Company's ordinary shares on the determination
of whether it is a passive foreign investment company; and other
factors discussed under the heading "Risk Factors" in ReWalk's
annual report on Form 10-K for the year ended December 31,
2019 filed with the SEC and other documents
subsequently filed with or furnished to the SEC. Any
forward-looking statement made in this press release speaks only as
of the date hereof. Factors or events that could cause ReWalk's
actual results to differ from the statements contained herein may
emerge from time to time, and it is not possible for ReWalk to
predict all of them. Except as required by law, ReWalk undertakes
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise.
Investor Contact:Ori GonChief
Financial Officer ReWalk Robotics Ltd.T:
+972-4-9590123 E: investorrelations@rewalk.com
ReWalk Robotics (NASDAQ:RWLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
ReWalk Robotics (NASDAQ:RWLK)
Historical Stock Chart
From Apr 2023 to Apr 2024